Leaflet: information for the user
DuoPlavin 75 mg /75 mg film-coated tablets
DuoPlavin 75 mg /100 mg film-coated tablets
clopidogrel/acid acetylsalicylic
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What isDuoPlavinand what it is used for
2. What you need to know before starting to takeDuoPlavin
3. How to takeDuoPlavin
4. Possible side effects
5. Storage ofDuoPlavin
6. Contents of the pack and additional information
DuoPlavin contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medications called antiplatelet agents. Platelets are very small cells found in the blood that aggregate when the blood clots. Antiplatelet agents, by preventing this aggregation in some types of blood vessels (called arteries), reduce the likelihood of blood clots (a process called atherothrombosis) forming.
DuoPlavin is administered to adults to prevent blood clots from forming in hardened arteries that may cause atherothrombotic effects (such as cerebral infarction, myocardial infarction, or death).
You have been prescribed DuoPlavin in place of two separate medications, clopidogrel and ASA, to help prevent blood clots from forming since you have experienced a severe type of chest pain, known as unstable angina or myocardial infarction (heart attack). For the treatment of this disease, your doctor may need to place a stent in the obstructed or narrowed artery to restore adequate blood flow.
Do not take DuoPlavin
Warnings and Precautions
Before starting treatment with DuoPlavin, inform your doctor if you are in any of the following situations:
During treatment with DuoPlavin:
Children and adolescents
DuoPlavin is not intended to be administered to children or adolescents under 18 years of age. There is a possible association between acetylsalicylic acid (ASA) and Reye's syndrome when products containing ASA are administered to children or adolescents with viral infections. Reye's syndrome is a rare and potentially fatal disease.
Taking DuoPlavin with other medications
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication.
Some medications may affect the use of DuoPlavin or vice versa.
You must inform your doctor specifically if you are taking:
You must discontinue another treatment with clopidogrel while taking DuoPlavin.
A single dose of ASA administered sporadically (not exceeding 1,000 mg in 24 hours) generally should not cause any problems, but prolonged use of ASA in other circumstances should be consulted with your doctor or pharmacist.
Pregnancy and breastfeeding
Do not take DuoPlavin during the third trimester of pregnancy.
It is recommended not to take this medication during the first and second trimesters of pregnancy.
If you are pregnant or think you may be pregnant, inform your doctor or pharmacist before taking DuoPlavin. If you become pregnant while taking DuoPlavin, consult your doctor immediately as it is not recommended to take DuoPlavin during pregnancy.
You should not breastfeed your child while using this medication.
If you are in a breastfeeding period or plan to breastfeed your child, inform your doctor before taking this medication.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
DuoPlavin should not affect your ability to drive or operate machinery.
DuoPlavin contains lactose
If your doctor has indicated that you have an intolerance to certain sugars (e.g. lactose), consult with him before taking this medication.
DuoPlavin contains hydrogenated ricin oil
This may cause stomach discomfort or diarrhea.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is one DuoPlavin tablet per day, administered orally, with a glass of water, with or without food.
You should take your medication at the same time every day.
Your doctor will determine the time you need to take DuoPlavin based on your situation. If you have had a heart attack, it should be prescribed for at least four weeks. However, you should continue taking it as long as your doctor continues to prescribe it.
If you take more DuoPlavin than you should
Contact your doctor or go to the nearest hospital emergency department, as there is a higher risk of bleeding.
If you forget to take DuoPlavin
If you forget to take a dose of DuoPlavin, but remember before 12 hours have passed since the time when you should have taken the medication, take the tablet immediately and the next one at the usual time.
If you forget for more than 12 hours, simply take the next dose at the usual time. Do not take a double dose to compensate for a missed tablet.
In the 14, 28, and 84-tablet formats, you can check the last day you took a DuoPlavin tablet by looking at the calendar printed on the blister pack.
If you interrupt treatment with DuoPlavin
Do not interrupt your treatment unless your doctor tells you to Contact your doctor before interrupting or restarting your treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, DuoPlavin may cause side effects, although not everyone will experience them.
Contact your doctor immediately if you experience:
The most common side effect seen with DuoPlavin is bleeding.Bleeding can appear in the stomach or intestine, bruises, hematomas (abnormal bleeding or bruises under the skin), nasal bleeding, blood in urine. There have also been reported a reduced number of cases of: bleeding of the blood vessels of the eyes, intracranial bleeding (especially in elderly patients), pulmonary or joint bleeding.
If you experience prolonged bleeding while taking DuoPlavin
If you cut or get a wound, it is possible that bleeding may take a little longer to stop than normal. This is related to the mechanism of action of the medication, as it prevents the blood's ability to form clots. For minor cuts or wounds, such as cutting during shaving, this usually does not matter. However, if you are concerned about your bleeding, consult your doctor immediately (see section 2 “Warnings and precautions”).
Other side effects are:
Frequent side effects(may affect up to 1 in 10 people):
Diarrhea, abdominal pain, indigestion, or heartburn.
Rare side effects (may affect up to 1 in 100 people):
Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in the stomach or intestine, rashes, itching, blisters on the skin.
Rare side effects (may affect up to 1 in 1,000 people):
Dizziness, breast enlargement in men.
Very rare side effects (may affect up to 1 in 10,000 people):
Jaundice (yellowing of the skin and/or eyes); heartburn and/or esophagus (throat) burning; severe abdominal pain with or without back pain; fever, difficulty breathing, sometimes associated with coughing; generalized allergic reactions (e.g., feeling of general heat with sudden general discomfort until fainting); swelling of the mouth; blisters on the skin, skin allergy; inflammation of the mouth (stomatitis); decreased blood pressure; confusion; hallucinations; joint pain; muscle pain; changes in taste or loss of taste of food, inflammation of small blood vessels.
Side effects of unknown frequency (cannot be estimated from available data):
Perforated ulcer, ringing in the ears, hearing loss, sudden and life-threatening allergic reactions or hypersensitivity reactions with chest pain or abdominal pain, kidney disease, low blood sugar, gout (disease with pain that courses with inflammation of the joints caused by uric acid crystals) and worsening of food allergies, a particular form of anemia (decrease in the number of red blood cells) (see section 2 “Warnings and precautions”), swelling.
Your doctor may also observe changes in your blood or urine test results.
Reporting side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect that does not appear in this prospectus.You can also report them directly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the carton and on the blister pack after CAD. The expiration date is the last day of the month indicated.
Store below 25 °C.
Do not use this medication if you observe any visible sign of deterioration.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
DuoPlavin 75 mg /75 mg film-coated tablets
The active ingredients are clopidogrel and acetylsalicylic acid (ASA). Each tablet contains 75 mg of clopidogrel (as hydrogen sulfate) and 75 mg of acetylsalicylic acid.
The other components are:
- Core: mannitol (E421), macrogol 6000, microcrystalline cellulose, hydroxypropylcellulose, cornstarch, hydrogenated ricin oil (see section 2 “DuoPlavin contains hydrogenated ricin oil”), stearic acid, and colloidal anhydrous silica.
- Tablet coating: lactose monohydrate (see section 2 “DuoPlavin contains lactose”), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), and yellow iron oxide (E172).
- Lacquer: carnauba wax.
DuoPlavin 75 mg /100 mg film-coated tablets
The active ingredients are clopidogrel and acetylsalicylic acid (ASA). Each tablet contains 75 mg of clopidogrel (as hydrogen sulfate) and 100 mg of acetylsalicylic acid.
The other components are:
- Core: mannitol (E421), macrogol 6000, microcrystalline cellulose, hydroxypropylcellulose, cornstarch, hydrogenated ricin oil (see section 2 “DuoPlavin contains hydrogenated ricin oil”), stearic acid, and colloidal anhydrous silica.
- Tablet coating: lactose monohydrate (see section 2 “DuoPlavin contains lactose”), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), and red iron oxide (E172).
- Lacquer: carnauba wax.
DuoPlavin 75 mg /75 mg film-coated tablets
DuoPlavin 75 mg/75 mg film-coated tablets (tablets) are oval, slightly biconvex, yellow in color, and have “C75” and “A75” engraved on opposite faces.
DuoPlavin is available in cartons containing:
DuoPlavin 75 mg /100 mg film-coated tablets
DuoPlavin 75 mg/100 mg film-coated tablets are oval, slightly biconvex, pale pink in color, and have “C75” and “A100” engraved on opposite faces.
DuoPlavin is available in cartons containing:
Only some pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
Manufacturer:
Sanofi Winthrop Industrie
1, Rue de la Vierge,Ambarès & Lagrave, F-33565 Carbon Blanc cedex, France.
For further information about this medicinal product, please consult the representative of the marketing authorization holder in your country.
België/Belgique/Belgien Sanofi Belgium Tél/Tel:+32 (0)2 710 54 00 | Luxembourg/Luxemburg Sanofi Belgium Tél/Tel:+32 (0)2 710 54 00 (Belgique/Belgien) |
???????? Swixx Biopharma EOOD ???.: +359 (0)2 4942 480 | Magyarország SANOFI-AVENTIS Zrt. Tel.: +36 1505 0050 |
Ceská republika sanofi-aventis, s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Danmark Sanofi A/S Tlf: +45 45 16 70 00 | Nederland Sanofi B.V. Tel: +3120 245 4000 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel.: 0800 52 52 010 Tel. aus dem Ausland: +49 69305 21 131 | Norge sanofi-aventis Norge AS Tlf: +47 67 10 71 00 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Österreich sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
Ελλ?δα Sanofi-Aventis Μονοπρ?σωπη AEBE Τηλ: +30 210 900 16 00 | Polska sanofi-aventis Sp. z o.o. Tel.: +48 22280 00 00 |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi - Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 |
France SanofiWinthrop Industrie Tél: 0 800 222 555 Appel depuis l’étranger : +33 1 57 63 23 23 Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | România Sanofi Romania SRL Tel: +40(0) 21 317 31 36 |
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1235 51 00 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia Sanofi S.r.l. Tel: 800 536 389 | Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 |
Κ?προς C.A. Papaellinas Ltd. Τηλ: +357 22 741741 | Sverige Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvija Tel: +371 6 616 47 50 | United Kingdom(Northern Ireland) sanofi-aventis Ireland Ltd.T/A SANOFI Tel:+44 (0) 800 035 2525 |
Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Last update of the summary of product characteristics:
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.